6532 Federal Register / Vol. 89, No. 22 / Thursday, February 1, 2024 / Notices 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Tami Jo Kingsbury, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 710Q, 

Bethesda, MD 20892, (410) 274–1352, 

tami.kingsbury@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Special 

Topics: Noninvasive Neuromodulation and 

Neuroimaging Technologies. 

Date: February 23, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Marriott Georgetown, 

1221 22nd Street NW, Washington, DC 

20037. 

Contact Person: Pablo M. Blazquez Gamez, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 435–1042, 

pablo.blazquezgamez@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Collaborative Applications: Clinical Studies 

of Mental Illness (Collaborative R01). 

Date: February 23, 2024. 

Time: 4:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Shivakumar V. Chittari, 

Ph.D., Scientific Review Officer, National 

Institutes of Health, Center for Scientific 

Review, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–408–9098, chittari.shivakumar@

nih.gov. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Neurodifferentiation, 

Plasticity, Regeneration and Rhythmicity 

Study Section. 

Date: February 26–27, 2024. 

Time: 9:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jacek Topczewski, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1002A1, 

Bethesda, MD 20892, (301) 594–7574, 

topczewskij2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: January 26, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–01958 Filed 1–31–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine and Oral 

Fluid Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITFs) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs using Urine or Oral Fluid 

(Mandatory Guidelines). 

FOR FURTHER INFORMATION CONTACT: 

Anastasia Flanagan, Division of 

Workplace Programs, SAMHSA/CSAP, 

5600 Fishers Lane, Room 16N06B, 

Rockville, Maryland 20857; 240–276– 

2600 (voice); Anastasia.Flanagan@

samhsa.hhs.gov (email). 

SUPPLEMENTARY INFORMATION: In 

accordance with section 9.19 of the 

Mandatory Guidelines, a notice listing 

all currently HHS-certified laboratories 

and IITFs is published in the Federal 

Register during the first week of each 

month. If any laboratory or IITF 

certification is suspended or revoked, 

the laboratory or IITF will be omitted 

from subsequent lists until such time as 

it is restored to full certification under 

the Mandatory Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

internet at https://www.samhsa.gov/ 

workplace/resources/drug-testing/ 

certified-lab-list. 

The Department of Health and Human 

Services (HHS) notifies Federal agencies 

of the laboratories and Instrumented 

Initial Testing Facilities (IITFs) 

currently certified to meet the standards 

of the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines) using Urine and 

of the laboratories currently certified to 

meet the standards of the Mandatory 

Guidelines using Oral Fluid. 

The Mandatory Guidelines using 

Urine were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); and on January 

23, 2017 (82 FR 7920). 

The Mandatory Guidelines using Oral 

Fluid were first published in the 

Federal Register on October 25, 2019 

(84 FR 57554) with an effective date of 

January 1, 2020. 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 

of Public Law 100–71 and allowed urine 

drug testing only. The Mandatory 

Guidelines using Urine have since been 

revised, and new Mandatory Guidelines 

allowing for oral fluid drug testing have 

been published. The Mandatory 

Guidelines require strict standards that 

laboratories and IITFs must meet in 

order to conduct drug and specimen 

validity tests on specimens for Federal 

agencies. HHS does not allow IITFs to 

conduct oral fluid testing. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines using Urine and/ 

or Oral Fluid. An HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that the test facility has met minimum 

standards. HHS does not allow IITFs to 

conduct oral fluid testing. 

HHS-Certified Laboratories Approved 

To Conduct Oral Fluid Drug Testing 

In accordance with the Mandatory 

Guidelines using Oral Fluid dated 

October 25, 2019 (84 FR 57554), the 

following HHS-certified laboratories 

meet the minimum standards to conduct 

drug and specimen validity tests on oral 

fluid specimens: 

At this time, there are no laboratories 

certified to conduct drug and specimen 

validity tests on oral fluid specimens. 

HHS-Certified Instrumented Initial 

Testing Facilities Approved To Conduct 

Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified IITFs meet the minimum 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 22 / Thursday, February 1, 2024 / Notices 6533 

standards to conduct drug and specimen 

validity tests on urine specimens: 

Dynacare,* 6628 50th Street NW, 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190 (Formerly: GammaDynacare Medical Laboratories). 

HHS-Certified Laboratories Approved 

To Conduct Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified laboratories meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823 (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.). 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.). 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917. 

Desert Tox, LLC, 5425 E Bell Rd., Suite 

125, Scottsdale, AZ 85254, 602–457– 

5411/623–748–5045. 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890. 

Dynacare,* 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630 (Formerly: GammaDynacare Medical Laboratories). 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609. 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.). 

Laboratory Corporation of America, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295 

(Formerly: Legacy Laboratory Services 

Toxicology MetroLab). 

Laboratory Corporation of America 

Holdings, 7207 N Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 TW Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339 (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

MedTox Laboratories, Inc., 402 W 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088. Testing for Veterans Affairs 

(VA) Employees Only. 

Omega Laboratories, Inc.,* 2150 

Dunwin Drive, Unit 1 & 2, 

Mississauga, ON, Canada L5L 5M8, 

289–919–3188. 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942 (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Phamatech, Inc., 15175 Innovation 

Drive, San Diego, CA 92128, 888– 

635–5840. 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

U.S. Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085, Testing for 

Department of Defense (DoD) 

Employees Only. 

* The Standards Council of Canada (SCC) 

voted to end its Laboratory Accreditation 

Program for Substance Abuse (LAPSA) 

effective May 12, 1998. Laboratories certified 

through that program were accredited to 

conduct forensic urine drug testing as 

required by U.S. Department of 

Transportation (DOT) regulations. As of that 

date, the certification of those accredited 

Canadian laboratories will continue under 

DOT authority. The responsibility for 

conducting quarterly performance testing 

plus periodic on-site inspections of those 

LAPSA-accredited laboratories was 

transferred to the U.S. HHS, with the HHS’ 

NLCP contractor continuing to have an active 

role in the performance testing and 

laboratory inspection processes. Other 

Canadian laboratories wishing to be 

considered for the NLCP may apply directly 

to the NLCP contractor just as U.S. 

laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (61 FR 

37015) as meeting the minimum 

standards of the Mandatory Guidelines 

published in the Federal Register on 

January 23, 2017 (82 FR 7920). After 

receiving DOT certification, the 

laboratory will be included in the 

monthly list of HHS-certified 

laboratories and participate in the NLCP 

certification maintenance program. 

Anastasia D. Flanagan, 

Public Health Advisor, Division of Workplace 

Programs. 

[FR Doc. 2024–01981 Filed 1–31–24; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2023–0928] 

Shipping Safety Fairways 

Environmental Impact Public Scoping 

Meetings 

AGENCY: Coast Guard, DHS. 

ACTION: Notice. 

SUMMARY: The Coast Guard announced a 

series of public meetings to solicit 

feedback on the potential environmental 

impact of shipping safety fairways along 

the Atlantic coast. The time of two of 

the meetings has been changed. This 

notice announces the new times for the 

Norfolk and virtual public meetings. 

The email address for the Coast Guard’s 

point of contact with regard to the 

Atlantic coast fairways has also been 

updated. 

FOR FURTHER INFORMATION CONTACT: For 

information about this document call or 

email Maureen Kallgren, Coast Guard; 

telephone 202–372–1561, email 

Maureen.R.Kallgren2@uscg.mil. 

SUPPLEMENTARY INFORMATION: The notice 

published on January 23, 2024, 

announced a series of public meetings. 

89 FR 4320. The February 12 meeting at 

the Jordan Newby Branch at Broad 

Creek of Norfolk Public Library has been 

moved to 6 p.m.–8 p.m. EST. The 

virtual meeting will take place on 

February 15 from 4 p.m.–6 p.m. EST at 

https://www.zoomgov.com/j/ 

1616731053. 

This notice is issued under authority 

found in 42 U.S.C. 4332. 

Dated: January 26, 2024. 

Steven E. Ramassini, 

Chief, Office of Navigation Systems. 

[FR Doc. 2024–02020 Filed 1–31–24; 8:45 am] 

BILLING CODE 9110–04–P 


ddrumheller on DSK120RN23PROD with NOTICES1